Mutational Analysis of BRAF Inhibitor–Associated Squamoproliferative Lesions

In recent years, there has been increasing use of BRAF-inhibiting drugs for the treatment of various malignancies, including melanoma. However, these agents are associated with the development of other nonmelanoma skin lesions, in particular squamoproliferative lesions such as keratoacanthomas (KAs), squamous cell carcinomas, and BRAF inhibitor–associated verrucous keratoses. The molecular pathogenesis of these lesions is of interest, not only for therapeutic reasons, but also for the insight it might provide into the development of similar lesions in a sporadic setting.

Source: Journal of Molecular Diagnostics - August 25, 2015 Category: Pathology Authors: Britt Clynick, Tania Tabone, Kathryn Fuller, Wendy Erber, Katie Meehan, Michael Millward, Benjamin A. Wood, Nathan T. Harvey Tags: Regular Article Source Type: research